{
  "meta": {
    "data_length": 1,
    "message": "Indication id ind:ema.imfinzi:2 retrieved successfully",
    "request_url": "http://api.moalmanac.org/indications?indication_id=ind%3Aema.imfinzi%3A2",
    "status": "success",
    "status_code": 200,
    "timestamp_elapsed": 0.004536,
    "timestamp_received": "2026-04-23T23:25:37.787132+00:00Z",
    "timestamp_returned": "2026-04-23T23:25:37.791668+00:00Z",
    "trace_id": "79b5cb07-85f6-464c-b7e3-86a6e1190a52"
  },
  "service": {
    "github": "https://github.com/vanallenlab/moalmanac-db",
    "name": "Molecular Oncology Almanac",
    "license": "GPL-2.0",
    "release": "draft",
    "url": "https://dev.moalmanac.org",
    "last_updated": "2026-04-09"
  },
  "data": [
    {
      "id": "ind:ema.imfinzi:2",
      "indication": "IMFINZI in combination with carboplatin and paclitaxel is indicated for the first-line treatment of adults with primary advanced or recurrent endometrial cancer who are candidates for systemic therapy, followed by maintenance treatment with IMFINZI as monotherapy in endometrial cancer that is mismatch repair deficient (dMMR) or IMFINZI in combination with olaparib in endometrial cancer that is mismatch repair proficient (pMMR).",
      "initial_approval_date": "2024-08-19",
      "initial_approval_url": "https://www.ema.europa.eu/en/documents/variation-report/imfinzi-h-c-1049-ws-2463-epar-assessment-report-variation_en.pdf",
      "description": "The European Medicines Agency (EMA) has authorized durvalumab in combination with carboplatin and paclitaxel for the first-line treatment of adult patients with primary advanced or recurrent endometrial cancer who are candidates for systemic therapy, followed by maintenance treatment with durvalumab as monotherapy in endometrial cancer that is mismatch repair deficient (dMMR) or durvalumab in combination with olaparib in endometrial cancer that is mismatch repair proficient (pMMR).",
      "raw_biomarkers": "mismatch repair deficient (dMMR) or mismatch repair proficient (pMMR).",
      "raw_cancer_type": "Endometrial cancer",
      "raw_therapeutics": "Imfinzi (durvalumab) in combination with carboplatin and paclitaxel followed by Imfinzi (durvalumab) as monotherapy for endometrial cancer that is mismatch repair deficient (dMMR) or Imfinzi (durvalumab) in combination with carboplatin and paclitaxel followed by Imfinzi (durvalumab) in combination with olaparib for endometrial cancer that is mismatch repair proficient (pMMR).",
      "icd10": null,
      "regimen_code": null,
      "reimbursement_category": null,
      "reimbursement_date": null,
      "reimbursement_details": null,
      "date_regular_approval": null,
      "date_accelerated_approval": null,
      "document": {
        "id": "doc:ema.imfinzi",
        "type": "Document",
        "documentType": "Regulatory approval",
        "name": "Imfinzi (durvalumab) [product information]. EMA.",
        "title": null,
        "aliases": [],
        "description": "AstraZeneca AB. Imfinzi (durvalumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/imfinzi-epar-product-information_en.pdf. Revised July 2025. Accessed August 29, 2025.",
        "urls": [
          "https://www.ema.europa.eu/en/medicines/human/EPAR/imfinzi",
          "https://www.ema.europa.eu/en/documents/product-information/imfinzi-epar-product-information_en.pdf"
        ],
        "doi": null,
        "pmid": null,
        "extensions": [
          {
            "name": "agent",
            "value": {
              "id": "ema",
              "type": "Agent",
              "agentType": "organization",
              "name": "European Medicines Agency",
              "description": "Regulatory agency that approves medicines for use in the European Union.",
              "extensions": [
                {
                  "name": "last_updated",
                  "value": "2025-10-01",
                  "description": ""
                },
                {
                  "name": "url",
                  "value": "https://www.ema.europa.eu/en/medicines",
                  "description": ""
                }
              ]
            },
            "description": "The organization that published this document."
          },
          {
            "name": "company",
            "value": "AstraZeneca AB.",
            "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents."
          },
          {
            "name": "drug_name_brand",
            "value": "Imfinzi",
            "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents."
          },
          {
            "name": "drug_name_generic",
            "value": "durvalumab",
            "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents."
          },
          {
            "name": "first_publication_date",
            "value": "2018-10-30",
            "description": "The publication date for the initial version of this document."
          },
          {
            "name": "identification_number",
            "value": null,
            "description": "Identification number used by the publishing organization."
          },
          {
            "name": "publication_date",
            "value": "2025-07-11",
            "description": "The publication date for the document."
          },
          {
            "name": "status",
            "value": "Active",
            "description": "Whether this document is Active or Deprecated within moalmanac-db."
          }
        ]
      }
    }
  ]
}